For those who have been following the story more than me, what are the chances cabozantinib meets the primary endpoint in MTC (believe results are due by end of Q3 (September 30).
Picked up a small lot for a trade a couple of weeks ago. (along with CLDX, ARQL, more CRIS, more ARIA, more ARRY). If all works out, I might have to send Standard & Poors a bouquet from FTD.
TIA